Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NRAS G12V |
| Therapy | Daraxonrasib |
| Indication/Tumor Type | melanoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NRAS G12V | melanoma | sensitive | Daraxonrasib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Rasonque (daraxonrasib) suppressed Erk activation and inhibited proliferation in transformed melanocytes expressing NRAS G12V in culture (PMID: 42562950). | 42562950 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42562950) | RAF1 S257L/S259F hotspot mutations: functional characterization and intrinsic resistance to the RAS(ON) inhibitor daraxonrasib in melanoma. | Full reference... |